Unicycive Therapeutics (NASDAQ:UNCY) Price Target Lowered to $40.00 at Guggenheim

Unicycive Therapeutics (NASDAQ:UNCY) had its target price trimmed by Guggenheim from $46.00 to $40.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

UNCY has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Westpark Capital began coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating on the stock. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $27.67.

Unicycive Therapeutics Trading Down 2.7%

UNCY opened at $6.93 on Thursday. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $11.00. The firm has a 50 day moving average of $6.67 and a two-hundred day moving average of $5.79. The firm has a market capitalization of $174.91 million, a PE ratio of -3.19 and a beta of 1.81.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). As a group, analysts predict that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC purchased a new stake in Unicycive Therapeutics during the second quarter worth $55,000. JPMorgan Chase & Co. increased its holdings in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Unicycive Therapeutics in the fourth quarter worth about $226,000. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the third quarter worth about $182,000. Finally, State Street Corp boosted its stake in shares of Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after acquiring an additional 10,400 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Guggenheim retained a “Buy” rating while lowering its price target from $46 to $40 — the new PT still implies a very large upside vs. the current share price, which can support bullish sentiment if the company hits clinical milestones. Guggenheim price target cut to $40
• Positive Sentiment: Noble Financial nudged a number of near-term quarterly estimates higher — Q1 2026 from ($0.47) to ($0.45), Q2 2026 from ($0.54) to ($0.52), and Q3 2026 from $0.74 to $0.79 — suggesting modestly improving near-term operational expectations. MarketBeat: Noble Financial raises Q1–Q3 estimates
• Positive Sentiment: Retail interest has surged this week (reports say a ~150% spike in retail buzz), which can produce sharp, momentum-driven upside ahead of binary events such as drug-approval outcomes. This increases short-term volatility and the chance of rapid price moves. UNCY retail buzz explodes 150%
• Neutral Sentiment: Consensus estimates remain mixed: market consensus for the current full year is still negative (around -$0.23 EPS), which contrasts with some analysts’ multi-quarter positive numbers — creating uncertainty about the timing and sustainability of profitability. MarketBeat consensus data
• Negative Sentiment: Noble Financial lowered its FY2026 outlook (from $1.02 to $0.85) and reduced Q4 2026 estimates (from $1.11 to $0.87), which is a downgrade to longer-term earnings optimism and could weigh on the stock if investors focus on the reduced full-year trajectory. MarketBeat: Noble lowers FY/Q4 estimates

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.